Application and development of Organ-on-a-Chip technology in cancer therapy

Area of Science:

• Biotechnology
• Cancer Research
• Microfluidics

Background:

• Cancer therapy is hindered by tumor heterogeneity, complex tumor microenvironments (TME), and treatment resistance.
• Traditional 2D cell cultures lack the physiological complexity to accurately model tumors.
• Organoid-on-a-Chip (OoC) technology offers a solution by integrating microfluidics and tissue engineering.

Purpose of the Study:

• To highlight the advancements and potential of Organoid-on-a-Chip (OoC) technology in cancer research.
• To demonstrate OoC's ability to create physiologically accurate 3D tumor models.
• To discuss the impact of OoC on drug screening, toxicity testing, and personalized oncology.

Main Methods:

• Development of OoC platforms integrating microfluidics, tissue engineering, and cell biology.
• Utilizing patient-derived organoids (PDOs) to retain parental tumor characteristics.
• Incorporating vascularization and multi-organ interactions into OoC models.

Main Results:

• OoC technology successfully simulates TME dynamics, including vascularization and multi-organ interactions.
• Patient-derived organoids show high drug-response accuracy (>87%) in colorectal cancer models.
• Vascularized tumor chips enable the study of angiogenic dynamics and drug efficacy.

Conclusions:

• OoC technology represents a significant advancement over traditional models for cancer research.
• OoC platforms are crucial for drug screening, toxicity testing, and advancing personalized cancer therapy.
• Further development in multi-organ integration and policy alignment is needed to fully realize OoC's potential in replacing animal models and enhancing precision medicine.